دورية أكاديمية
أعرض في EDS

Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.

التفاصيل البيبلوغرافية
العنوان: Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.
المؤلفون: Mangas KM; Department of Microbiology and Immunology, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia., Buultjens AH; Department of Microbiology and Immunology, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia., Porter JL; Department of Microbiology and Immunology, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia., Baines SL; Department of Microbiology and Immunology, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia., Marion E; CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France., Marsollier L; CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France., Tobias NJ; Molekulare Biotechnologie, Fachbereich Biowissenschaften, Goethe-Universität Frankfurt, Frankfurt am Main, Germany.; LOEWE Centre for Translational Biodiversity in Genomics (TBG), Frankfurt am Main, Germany., Pidot SJ; Department of Microbiology and Immunology, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia., Quinn KM; Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia., Price DJ; Victorian Infectious Diseases Reference Laboratory Epidemiology Unit at The Peter Doherty Institute for Infection & Immunity, The University of Melbourne and Royal Melbourne Hospital, Parkville, Victoria, Australia.; Centre for Epidemiology & Biostatistics, Melbourne School of Population & Global Health, The University of Melbourne, Melbourne, Victoria, Australia., Kedzierska K; Department of Microbiology and Immunology, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia., Zeng W; Department of Microbiology and Immunology, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia., Jackson DC; Department of Microbiology and Immunology, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia., Chua BY; Department of Microbiology and Immunology, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia., Stinear TP; Department of Microbiology and Immunology, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia tstinear@unimelb.edu.au.
المصدر: Infection and immunity [Infect Immun] 2020 Feb 20; Vol. 88 (3). Date of Electronic Publication: 2020 Feb 20 (Print Publication: 2020).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Society For Microbiology Country of Publication: United States NLM ID: 0246127 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1098-5522 (Electronic) Linking ISSN: 00199567 NLM ISO Abbreviation: Infect Immun Subsets: MEDLINE
أسماء مطبوعة: Publication: Washington, DC : American Society For Microbiology
Original Publication: [Bethesda, Md.] American Society for Microbiology.
مواضيع طبية MeSH: Buruli Ulcer*/immunology , Buruli Ulcer*/prevention & control, Bacterial Vaccines/*immunology , Mycobacterium ulcerans/*immunology , Vaccination/*methods, Animals ; BCG Vaccine/immunology ; Interleukins/metabolism ; Mice ; Multivariate Analysis
مستخلص: The neglected tropical disease Buruli ulcer (BU) is an infection of subcutaneous tissue with Mycobacterium ulcerans There is no effective vaccine. Here, we assessed an experimental prime-boost vaccine in a low-dose murine tail infection model. We used the enoyl reductase (ER) domain of the M. ulcerans mycolactone polyketide synthases electrostatically coupled with a previously described Toll-like receptor 2 (TLR-2) agonist-based lipopeptide adjuvant, R 4 Pam 2 Cys. Mice were vaccinated and then challenged via tail inoculation with 14 to 20 CFU of a bioluminescent strain of M. ulcerans Mice receiving either the experimental ER vaccine or Mycobacterium bovis bacillus Calmette-Guérin (BCG) were equally protected, with both groups faring significantly better than nonvaccinated animals ( P <  0.05). To explore potential correlates of protection, a suite of 29 immune parameters were assessed in the mice at the end of the experimental period. Multivariate statistical approaches were used to interrogate the immune response data to develop disease-prognostic models. High levels of interleukin 2 (IL-2) and low gamma interferon (IFN-γ) produced in the spleen best predicted control of infection across all vaccine groups. Univariate logistic regression revealed vaccine-specific profiles of protection. High titers of ER-specific IgG serum antibodies together with IL-2 and IL-4 in the draining lymph node (DLN) were associated with protection induced by the ER vaccine. In contrast, high titers of IL-6, tumor necrosis factor alpha (TNF-α), IFN-γ, and IL-10 in the DLN and low IFN-γ titers in the spleen were associated with protection following BCG vaccination. This study suggests that an effective BU vaccine must induce localized, tissue-specific immune profiles with controlled inflammatory responses at the site of infection.
(Copyright © 2020 American Society for Microbiology.)
References: PLoS Negl Trop Dis. 2013 Apr 25;7(4):e2183. (PMID: 23638204)
Bioinformatics. 2008 Jul 15;24(14):1632-8. (PMID: 18515276)
J Immunol. 2010 Feb 1;184(3):1436-44. (PMID: 20042571)
Appl Environ Microbiol. 2002 Sep;68(9):4623-8. (PMID: 12200321)
PLoS Negl Trop Dis. 2013 Oct 03;7(10):e2463. (PMID: 24098820)
PLoS Negl Trop Dis. 2008 Mar 19;2(3):e199. (PMID: 18350112)
J Infect Dis. 2009 Dec 1;200(11):1675-84. (PMID: 19863437)
PLoS Negl Trop Dis. 2019 Feb 19;13(2):e0007178. (PMID: 30779807)
J Immunol. 2011 Aug 15;187(4):1692-701. (PMID: 21742967)
Appl Environ Microbiol. 2004 Feb;70(2):1097-103. (PMID: 14766593)
Clin Exp Immunol. 2009 Aug;157(2):271-81. (PMID: 19604267)
Infect Immun. 2000 Feb;68(2):877-83. (PMID: 10639458)
Nature. 1970 Aug 15;227(5259):680-5. (PMID: 5432063)
PLoS Negl Trop Dis. 2015 Dec 01;9(12):e0004265. (PMID: 26625302)
Microbiology. 2005 Mar;151(Pt 3):683-692. (PMID: 15758215)
PLoS Negl Trop Dis. 2016 Jun 28;10(6):e0004808. (PMID: 27351976)
Immunol Cell Biol. 2016 Feb;94(2):169-76. (PMID: 26272554)
Science. 1999 Feb 5;283(5403):854-7. (PMID: 9933171)
Pulm Med. 2012;2012:745483. (PMID: 23251798)
Am J Trop Med Hyg. 2019 Dec;101(6):1312-1321. (PMID: 31595865)
J Exp Med. 2016 Dec 12;213(13):2885-2896. (PMID: 27821549)
Med J Aust. 1954 Mar 27;41(1 13):475-9. (PMID: 13164639)
Infect Immun. 2005 Oct;73(10):6299-310. (PMID: 16177301)
Infect Immun. 2007 May;75(5):2642-4. (PMID: 17325046)
PLoS Pathog. 2015 Jul 16;11(7):e1005011. (PMID: 26181660)
PLoS Negl Trop Dis. 2016 Feb 10;10(2):e0004450. (PMID: 26863011)
Microbes Infect. 2006 Jul;8(8):2075-81. (PMID: 16781179)
PLoS One. 2012;7(3):e33406. (PMID: 22413022)
Emerg Infect Dis. 2003 Jun;9(6):651-656. (PMID: 12780997)
Behav Genet. 2009 Sep;39(5):580-95. (PMID: 19526352)
BMC Genomics. 2008 Oct 07;9:462. (PMID: 18840298)
Lancet. 1999 Sep 18;354(9183):1013-8. (PMID: 10501380)
Cell Microbiol. 2005 Sep;7(9):1295-304. (PMID: 16098217)
Am J Trop Med Hyg. 2007 Jan;76(1):132-4. (PMID: 17255241)
Cell Death Dis. 2018 Mar 14;9(3):397. (PMID: 29540678)
Eur J Immunol. 2009 Oct;39(10):2865-76. (PMID: 19637228)
Nat Rev Drug Discov. 2012 Oct;11(10):763-76. (PMID: 23023676)
Front Immunol. 2019 Apr 30;10:917. (PMID: 31114578)
Emerg Infect Dis. 2018 Nov;24(11):1988-1997. (PMID: 30334704)
Immunol Cell Biol. 2016 Jan;94(1):101-8. (PMID: 26134269)
Appl Environ Microbiol. 2018 Apr 2;84(8):. (PMID: 29439984)
PLoS One. 2016 Nov 28;11(11):e0167059. (PMID: 27893778)
Lancet Infect Dis. 2018 Jun;18(6):650-656. (PMID: 29605498)
Open Forum Infect Dis. 2016 Feb 25;3(1):ofw013. (PMID: 26925431)
PLoS Negl Trop Dis. 2015 Aug 14;9(8):e0004011. (PMID: 26275222)
PLoS Negl Trop Dis. 2016 Dec 12;10(12):e0005229. (PMID: 27941982)
Infect Immun. 2007 Aug;75(8):3979-88. (PMID: 17517872)
Infect Immun. 2001 Mar;69(3):1704-7. (PMID: 11179346)
PLoS Negl Trop Dis. 2014 Jan 02;8(1):e2604. (PMID: 24392169)
Front Immunol. 2015 May 11;6:217. (PMID: 26029205)
J Theor Biol. 2008 May 7;252(1):24-38. (PMID: 18321531)
Infect Immun. 2001 Sep;69(9):5403-11. (PMID: 11500410)
PLoS Negl Trop Dis. 2015 Mar 05;9(3):e0003549. (PMID: 25742173)
Crit Rev Microbiol. 2015;41(3):389-98. (PMID: 24495096)
Front Immunol. 2018 Dec 20;9:2987. (PMID: 30619342)
J Immunol Methods. 2007 Dec 1;328(1-2):204-14. (PMID: 17804011)
Clin Infect Dis. 2003 Sep 15;37(6):e78-82. (PMID: 12955667)
Infect Immun. 2011 Jan;79(1):421-30. (PMID: 20974825)
Lancet. 2010 Feb 20;375(9715):664-72. (PMID: 20137805)
PLoS Negl Trop Dis. 2016 Feb 05;10(2):e0004431. (PMID: 26849213)
Am J Trop Med Hyg. 1974 Sep;23(5):919-23. (PMID: 4451232)
PLoS Negl Trop Dis. 2017 Aug 18;11(8):e0005800. (PMID: 28821017)
Lancet Glob Health. 2019 Jul;7(7):e912-e922. (PMID: 31200890)
Annu Rev Immunol. 2001;19:93-129. (PMID: 11244032)
Infect Immun. 2006 May;74(5):2917-24. (PMID: 16622230)
J Immunol. 2016 Mar 15;196(6):2690-8. (PMID: 26873988)
Clin Microbiol Rev. 2017 Dec 13;31(1):. (PMID: 29237707)
AIDS. 2010 Oct 23;24(16):2423-31. (PMID: 20827167)
J Autoimmun. 2015 Jun;60:1-11. (PMID: 25998834)
J Gen Virol. 2016 Dec;97(12):3205-3214. (PMID: 27902386)
PLoS Negl Trop Dis. 2014 Jul 10;8(7):e2968. (PMID: 25010421)
Front Immunol. 2017 Dec 15;8:1840. (PMID: 29326716)
Antimicrob Agents Chemother. 2010 Sep;54(9):3678-85. (PMID: 20566765)
Pathology. 1985 Oct;17(4):594-600. (PMID: 4094789)
PLoS Negl Trop Dis. 2015 Sep 22;9(9):e0004046. (PMID: 26393347)
Methods Mol Biol. 2008;494:247-61. (PMID: 18726578)
Clin Exp Immunol. 2006 Mar;143(3):445-51. (PMID: 16487243)
Lancet Glob Health. 2014 Jul;2(7):e422-30. (PMID: 25103396)
PLoS Negl Trop Dis. 2010 Nov 02;4(11):e872. (PMID: 21072233)
Genome Res. 2007 Feb;17(2):192-200. (PMID: 17210928)
Clin Diagn Lab Immunol. 2005 Jan;12(1):125-9. (PMID: 15642996)
PLoS Pathog. 2014 Apr 03;10(4):e1004061. (PMID: 24699819)
Tuberc Res Treat. 2014;2014:536976. (PMID: 24523962)
Vaccine. 2015 May 5;33(19):2232-2239. (PMID: 25825332)
PLoS One. 2013 Jul 23;8(7):e70520. (PMID: 23894666)
J Invest Dermatol. 2007 Mar;127(3):638-45. (PMID: 17068481)
PLoS Negl Trop Dis. 2011 Mar 15;5(3):e985. (PMID: 21423646)
Am J Trop Med Hyg. 1999 Nov;61(5):694-7. (PMID: 10586896)
PLoS Negl Trop Dis. 2017 Apr 14;11(4):e0005553. (PMID: 28410412)
J Exp Med. 2007 Jun 11;204(6):1395-403. (PMID: 17517970)
F1000Res. 2016 Nov 16;5:2676. (PMID: 28713544)
Chem Commun (Camb). 2003 Nov 21;(22):2822-3. (PMID: 14651122)
PLoS Negl Trop Dis. 2018 Mar 19;12(3):e0006323. (PMID: 29554096)
CMAJ. 2012 Jan 10;184(1):37-42. (PMID: 22143235)
Artif Intell Med. 2011 Oct;53(2):107-18. (PMID: 21821401)
Am Rev Tuberc. 1957 Jul;76(1):76-89. (PMID: 13444620)
J Immunol. 1999 Oct 1;163(7):3928-35. (PMID: 10490994)
Mol Pharm. 2019 May 6;16(5):2037-2047. (PMID: 30924661)
Curr Opin Chem Biol. 2011 Feb;15(1):48-56. (PMID: 21087894)
Mol Pharm. 2012 Sep 4;9(9):2710-8. (PMID: 22823162)
J Immunol. 2010 Jan 15;184(2):947-55. (PMID: 20008288)
Biomaterials. 2017 Aug;137:61-72. (PMID: 28544973)
Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1345-9. (PMID: 14736915)
Clin Exp Dermatol. 2005 Nov;30(6):649-51. (PMID: 16197379)
فهرسة مساهمة: Keywords: Buruli ulcer; Mycobacterium ulcerans; machine learning; mycolactone; polyketide synthase; vaccine
المشرفين على المادة: 0 (BCG Vaccine)
0 (Bacterial Vaccines)
0 (Interleukins)
تواريخ الأحداث: Date Created: 20191211 Date Completed: 20200423 Latest Revision: 20200820
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7035934
DOI: 10.1128/IAI.00753-19
PMID: 31818964
قاعدة البيانات: MEDLINE
الوصف
تدمد:1098-5522
DOI:10.1128/IAI.00753-19